Reset filter
Keywords
Melanoma ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

133 Search results.
Relevance Rating New first Old first

Eligibility Melanoma NCT02475213

- 5/8/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02475213

Eligibility Melanoma NCT02459067

- 5/8/19 - 1 form, 2 itemgroups, 29 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
ImmuniCell® in Patients With Advanced Cancers; ODM derived from: https://clinicaltrials.gov/show/NCT02459067

Eligibility Melanoma NCT02381314

- 5/7/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02381314

Eligibility Melanoma NCT00147550

- 10/19/16 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.; ODM derived from: https://clinicaltrials.gov/show/NCT00147550

Eligibility NCT00522834 Melanoma - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 13 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00522834

Eligibility DRKS00003621 NCT00518895 Melanoma - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 16 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00518895

Medication Form Melanoma (NCT01274338)

- 9/20/21 - 1 form, 6 itemgroups, 35 items, 1 language
Itemgroups: Header, On Treatment Reporting Period, OFF TREATMENT, Corticosteroid Medication, Immunosuppressant Medication, Hormonal Replacement Therapy Medication
E1609 Corticosteroid/Immunosuppressant/Hormone Replacement Medication Form Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery NCT01274338 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1F0BB2E-39FF-B3FA-E040-BB89AD430140

Melanoma Concomitant Medication NCT00110019 - Concomitant Medication Melanoma NCT00110019 E2603 No. 2169

- 3/26/15 - 1 form, 2 itemgroups, 29 items, 2 languages
Itemgroups: Header, Concomitant Medication
E2603 Concomitant Medication Form Form No. 2169 Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma NCT00110019 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E7D649ED-D8C9-54BD-E034-0003BA3F9857

Eligibility NCT00395070 Metastatic Melanoma - Eligibility

- 4/15/14 - 1 form, 2 itemgroups, 11 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00395070

Eligibility NCT01355120 Advanced Ocular Melanoma - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 35 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01355120

Melanoma Eligibility Interferon Alpha NCT00226408 - Eligibility Melanoma NCT00226408

- 6/6/15 - 1 form, 3 itemgroups, 45 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria, Medical concepts
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon ODM derived from http://clinicaltrials.gov/show/NCT00226408

Melanoma Adverse Event E1609 NCT01274338 - Adverse Event Melanoma (CTCAE v4) - Arm A NCT01274338

- 4/21/15 - 1 form, 5 itemgroups, 24 items, 1 language
Itemgroups: Header Module, ON TREATMENT, Adverse Event, Adverse event hematologic or metabolic, Other Adverse Events
E1609 Adverse Event Form (CTCAE v4) - Arm A Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery NCT01274338 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=97ED76E3-6554-CD9F-E040-BB89AD430E2E

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial